Release Date: September 15, 2025
Expiration Date: September 15, 2027
Activity Overview
The BURST CME™ format is an online, on-demand program designed to deliver concise modular education. In this second module, Jason M. Hafron, MD, discusses strategies for developing long-term monitoring plans for assessing prostate cancer risk based on individual factors and shared decision-making.
Target Audience
This educational activity is primarily directed toward urologists. Other clinicians who diagnose prostate cancer are welcome to participate as well.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement long-term monitoring strategies for patients with a low risk of prostate cancer.
Jason M. Hafron, MD
Chief Medical Officer and Medical Director of Research
Michigan Institute of Urology
Professor of Urology, William Beaumont School of Medicine
Disclosures: Consultant/Advisor: Astellas Pharma Inc, AstraZeneca, Dendreon Pharmaceuticals LLC, Immunis.AI, Janssen Biotech Inc, Lipella Pharmaceuticals LLC, Myriad Genetics Inc, Pfizer, Photocure, Sumitomo Pharma Co Ltd, Tolmar Pharmaceuticals Inc, UroGen Pharma Inc; Meeting Participant/Lecturer: Astellas Pharma Inc, Bayer, Blue Earth Diagnostics, Dendreon Pharmaceuticals LLC, Janssen Biotech Inc, Lantheus, Merck & Co Inc, Novartis, Pfizer, Photocure, Procept BioRobotics, Sumitomo Pharma Co, Tolmar Pharmaceuticals Inc, UroGen Pharma Inc; Scientific Study/Trial: Astellas Pharma Inc, AstraZeneca, Bayer, Dendreon Pharmaceuticals LLC, Immunis.AI, Janssen Biotech Inc, Lipella Pharmaceuticals LLC, Merck & Co Inc, Myriad Genetics Inc, Nucleix, Pfizer, Sumitomo Pharma Co.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.